Iovance, a Top 1% Biotech Stock, Plummets on Surprise Lung Cancer Twist

Iovance stock slumped Thursday, undercutting its 50-day line, amid new sustainability questions surrounding its experimental lung cancer treatment. About a quarter of patients with a form of metastatic lung cancer responded to treatment with Iovance Biotherapeutics’ (IOVA) drug lifileucel. But the release did not specify how long patients responded to treatment or describe specific safety and tolerability findings. Both…